Pregnancy in homozygous familial hypercholesterolemia - Importance of LDL-apheresis

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11150%2F15%3A10294646" target="_blank" >RIV/00216208:11150/15:10294646 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00179906:_____/15:10294646

Výsledek na webu

<a href="http://www.sciencedirect.com/science/article/pii/S1567568815000252" target="_blank" >http://www.sciencedirect.com/science/article/pii/S1567568815000252</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.atherosclerosissup.2015.02.024" target="_blank" >10.1016/j.atherosclerosissup.2015.02.024</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Pregnancy in homozygous familial hypercholesterolemia - Importance of LDL-apheresis

Popis výsledku v původním jazyce

Introduction: Rare cases of pregnancy in women with homozygous familial hypercholesterolemia (HFH) have been reported. HFH might pose significant risks for the mother and her fetus. Statins, the most potent agents for low-density lipoprotein (LDL) cholesterol reduction, are contraindicated; thus lipoprotein apheresis remains the only effective treatment. Case report: We report on a 34-year-old pregnant woman with HFH who was treated throughout the entire pregnancy by lipoprotein apheresis (immunoadsorption method). Increasing levels of LDL-cholesterol were stabilized at 9 e 10 mmol/L by lipoprotein apheresis (performed every 10 days). No complications were observed during the treatment procedures. Monitoring of the fetus revealed no impairment of the umbilical cord and blood flow in the uterine arteries, as well as no intrauterine growth retardation. The delivery was spontaneous and the child was breastfed for two months. Conclusion: Intensive treatment by lipoprotein apheresis is an e

Název v anglickém jazyce

Pregnancy in homozygous familial hypercholesterolemia - Importance of LDL-apheresis

Popis výsledku anglicky

Introduction: Rare cases of pregnancy in women with homozygous familial hypercholesterolemia (HFH) have been reported. HFH might pose significant risks for the mother and her fetus. Statins, the most potent agents for low-density lipoprotein (LDL) cholesterol reduction, are contraindicated; thus lipoprotein apheresis remains the only effective treatment. Case report: We report on a 34-year-old pregnant woman with HFH who was treated throughout the entire pregnancy by lipoprotein apheresis (immunoadsorption method). Increasing levels of LDL-cholesterol were stabilized at 9 e 10 mmol/L by lipoprotein apheresis (performed every 10 days). No complications were observed during the treatment procedures. Monitoring of the fetus revealed no impairment of the umbilical cord and blood flow in the uterine arteries, as well as no intrauterine growth retardation. The delivery was spontaneous and the child was breastfed for two months. Conclusion: Intensive treatment by lipoprotein apheresis is an e

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FE - Ostatní obory vnitřního lékařství

OECD FORD obor

—

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2015

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Atherosclerosis Supplements

ISSN

1567-5688

e-ISSN

—

Svazek periodika

18

Číslo periodika v rámci svazku

May

Stát vydavatele periodika

IE - Irsko

Počet stran výsledku

6

Strana od-do

134-139

Kód UT WoS článku

000353796000021

EID výsledku v databázi Scopus

2-s2.0-84928893285